• Call +1.858.633.0165 or Fax +1.858.633.0166 or Contact Us

Ipilimumab Inhibitor

For Research Use Only. Not for use in diagnostic procedures. Catalog #: MBS5759551

Ipilimumab anti-CTLA-4) is an immunomodulatory monoclonal antibody directed against the cell surface antigen CTLA-4 and also a type of immune checkpoint inhibitor. More details

Product Documentation
PDF
Sample Manual Insert View PDF
PDF
Testing Data View PDF
PDF
Certificate of Analysis (COA) View PDF
PDF
QC Report View PDF
PDF
Material Safety Data Sheet View PDF
PDF
Technical Datasheet View PDF
PDF
Protocol View PDF

Product Overview

Online Datasheet in PDF
Product Name
Ipilimumab, Inhibitor
Full Product Name
Ipilimumab
Product Synonym Names
Ipilimumab (anti-CTLA-4); anti-CTLA-4; MDX-010; BMS-73401
Form/Format
Solid. Powder
Purity/Purification
99.2%
Preparation and Storage
Store at -20 degree C for 3 years powder
-80 degree C for 2 years in solvent
Molecular Weight
148000
Solubility
<1mg/ml refers to the product slightly soluble or insoluble
CAS Number
477202-00-9
Target & IC50
CTLA-4
Cell Research
Objective: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells Concentrations: 0, 0.5, 5.0, and 50ug/mL. Incubation Time: 10-14 days Method: hPBMC were stimulated with anti-CD3 monoclonal antibody with or without ipilimumab and expanded for 10-14 days. ATC were harvested and armed with anti-CD3 x anti-EGFR BiAb (EGFRBi) or anti-CD3 x anti-CD20 BiAb (CD20Bi) to test for redirected cytotoxicity against COLO356/FG pancreatic cancer cell line or Burkitt's lymphoma cell line (Daudi). Cell lines: PBMC from healthy individuals; COLO356/FG (Pancreatic Cancer cell line) and Burkitt's lymphoma cell line

Product References and Citations for Ipilimumab, inhibitor

Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54.
Hu-Lieskovan S, et al. Combining targeted therapy with immunotherapy in BRAF-mutant melanoma: promise and challenges. J Clin Oncol. 2014 Jul 20;32(21):2248-54.
Giuseppe Tridente. Adverse Events with Biomedicines, 2013.
Giuseppe Tridente. Adverse Events with Biomedicines, 2013.
Yano H, et al. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014 Jul 9;12:191.
Yano H, et al. Ipilimumab augments antitumor activity of bispecific antibody-armed T cells. J Transl Med. 2014 Jul 9;12:191.
Selby MJ, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779
Selby MJ, et al. Preclinical Development of Ipilimumab and Nivolumab Combination Immunotherapy: Mouse Tumor Models, In Vitro Functional Studies, and Cynomolgus Macaque Toxicology. PLoS One. 2016 Sep 9;11(9):e0161779

Other Notes

Small volumes of Ipilimumab, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

Searchable Terms for Ipilimumab purchase

MBS5759551 is an inhibitor targeting Ipilimumab.
Request a Quote

Please fill out the form below and our representative will get back to you shortly.

MBS000000
Contact Us

Please fill out the form below and our representative will get back to you shortly.

MBS000000